No matches
Dermatology

CSU is Unpredictable in its Course and Duration

Dr. Hawkes highlights how Chronic Urticaria is a mast cell centric disease with moderate levels of spontaneous remission in patients.
Jason Hawkes
MD, MS
Jason Hawkes

Learning objectives

  • Highlight potential roles of cytokine and immune cell dysfunction in CSU pathogenesis including mast cell activation and immune cell trafficking
Tags
mast cellsdisease backgroundexpert insightssymptoms
MAT-US-2508501 v1.0 - P Expiration Date: 05/21/2027

About this expert

Dermatology

Jason Hawkes

MD, MS

Dr. Hawkes is a board-certified dermatologist and Investigator at the Oregon Medical Research Center in Portland, OR and is a current Councilor in the International Psoriasis Council and serves on the NPF Medical Board and Scientific Advisory Committee

See author’s profile
Jason Hawkes

Related resources

Assessment of Atopic Dermatitis Burden in Children and Adolescents
Dermatology
expert video

Assessment of Atopic Dermatitis Burden in Children and Adolescents

Comorbidities in Children and Adolescents with Atopic Dermatitis
Dermatology
expert video

Comorbidities in Children and Adolescents with Atopic Dermatitis

What is the disease burden of atopic dermatitis on children and their families
Dermatology
expert video

What is the disease burden of atopic dermatitis on children and their families

The Burden of Disease in Atopic Dermatitis
Dermatology
expert video

The Burden of Disease in Atopic Dermatitis

Explore the clinical presentations of bullous pemphigoid (BP), the steps for diagnosis, and the burden of disease.
Dermatology
Infographic

Bullous Pemphigoid (BP): Don't Miss the Diagnosis

Navigating Atopic Dermatitis and Hand and Foot Dermatitis: Clinical Manifestations and Pathophysiology
Dermatology
expert video

Navigating Atopic Dermatitis and Hand and Foot Dermatitis: Clinical Manifestations and Pathophysiology

Disease Modification Concepts in AD
Dermatology
expert video

Disease Modification Concepts in AD

Barrier disruption in AD and the development of environmental and food allergies
Dermatology
expert video

Barrier disruption in AD and the development of environmental and food allergies

Skin Barrier Dysfunction and Type 2 Inflammation in Atopic Dermatitis
Dermatology
videoanimation

Skin Barrier Dysfunction and Type 2 Inflammation in Atopic Dermatitis

How type 2 cytokines can amplify inflammatory response in CSU
Dermatology
expert video

How type 2 cytokines can amplify inflammatory response in CSU

Type 2 Inflammation and Infections
Type 2 Inflammation
slide presentation

Type 2 Inflammation and Infections

Bullous Pemphigoid Mechanism of Disease Video
Dermatology
videoanimation

Bullous Pemphigoid Mechanism of Disease Video

Diagnosis of Bullous Pemphigoid Interactive Patient Case
Dermatology
interactivity

Diagnosis of Bullous Pemphigoid Interactive Patient Case

Differential Diagnosis and Disease Onset in Older Adult Patients With AD
Dermatology
expert video

Differential Diagnosis and Disease Onset in Older Adult Patients With AD

Importance of Achieving Disease Control in Adults With Moderate-to-Severe AD
Dermatology
expert video

Importance of Achieving Disease Control in Adults With Moderate-to-Severe AD

Inflamm-aging: Systemic Inflammation and Frailty in Older Adults
Dermatology
expert video

Inflamm-aging: Systemic Inflammation and Frailty in Older Adults

Is Pediatric AD Linked to Other Allergic Diseases?
Dermatology
expert video

Is Pediatric AD Linked to Other Allergic Diseases?

Long-term Impacts of AD and the Potential Benefit of Early Intervention
Dermatology
expert video

Long-term Impacts of AD and the Potential Benefit of Early Intervention

New Data on the Systemic (Multi-Organ) Burden of AD in Children and the Need for Early Intervention
Dermatology
expert video

New Data on the Systemic (Multi-Organ) Burden of AD in Children and the Need for Early Intervention

Practical Considerations in Older Patients with AD
Dermatology
expert video

Practical Considerations in Older Patients with AD

The Benefits of Early Intervention in AD: More Than Skin Deep
Dermatology
expert video

The Benefits of Early Intervention in AD: More Than Skin Deep

The Benefits of Early Intervention in AD: More Than Skin Deep – Q&A Session and Conclusion
Dermatology
expert video

The Benefits of Early Intervention in AD: More Than Skin Deep – Q&A Session and Conclusion

The Cumulative Disease Burden of AD in Adult Patients
Dermatology
expert video

The Cumulative Disease Burden of AD in Adult Patients

What do we mean by disease control in AD?
Dermatology
expert video

What do we mean by disease control in AD?

The Burden of AD: More Than Skin Deep
Dermatology
Infographic

The Burden of AD: More Than Skin Deep

ADVENT On Air | First-hand Experience: Practical Insights On the Diagnosis and Assessment of Atopic Dermatitis of the Hands and Feet
Dermatology
Podcast

ADVENT On Air | First-hand Experience: Practical Insights On the Diagnosis and Assessment of Atopic Dermatitis of the Hands and Feet

ADVENT On Air | Exploring PN as a Distinct and Unique Disease
Dermatology
Podcast

ADVENT On Air | Exploring PN as a Distinct and Unique Disease

ADVENT On Air | Clinical Perspective on Pediatric Patients With Atopic Dermatitis
Dermatology
Podcast

ADVENT On Air | Clinical Perspective on Pediatric Patients With Atopic Dermatitis

The Patient Burden of Chronic Pruritus of Unknown Origin (CPUO)
Dermatology
Infographic

The Patient Burden of Chronic Pruritus of Unknown Origin (CPUO)

Stepping Into Hand and Foot Dermatitis
Dermatology
expert video

Stepping Into Hand and Foot Dermatitis

Understanding Disease Mechanisms
Dermatology
expert video

Understanding Disease Mechanisms

ADVENT On Air | Getting to the Diagnosis of AD in Pediatric Patients
Dermatology
Podcast

ADVENT On Air | Getting to the Diagnosis of AD in Pediatric Patients

ADVENT On Air | Defining AD in Pediatric Patients
Dermatology
Podcast

ADVENT On Air | Defining AD in Pediatric Patients

ADVENT On Air - Dermatology
Dermatology
Podcast

ADVENT On Air | Expert Discussions in Dermatology

Guideline-Based Diagnosis of Atopic Dermatitis
Dermatology
interactivity

Guideline-Based Diagnosis of Atopic Dermatitis

Etiology and Diagnosis of Bullous Pemphigoid
Dermatology
expert video

Etiology and Diagnosis of Bullous Pemphigoid

Pathophysiology of Blister Formation in Bullous Pemphigoid
Dermatology
expert video

Pathophysiology of Blister Formation in Bullous Pemphigoid

Unmet Needs for Bullous Pemphigoid (BP): Limitations of Diagnosis and Conventional Therapies
Dermatology
expert video

Unmet Needs for Bullous Pemphigoid (BP): Limitations of Diagnosis and Conventional Therapies

What We Know About Bullous Pemphigoid (BP): Challenges of the Various Clinical Manifestations, Diagnosis, and Burden for Patients and Caregiver
Dermatology
expert video

What We Know About Bullous Pemphigoid (BP): Challenges of the Various Clinical Manifestations, Diagnosis, and Burden for Patients and Caregivers

Mechanisms of Disease: Autoimmunity and Role of Type 2 Inflammation in BP
Dermatology
expert video

Mechanisms of Disease: Autoimmunity and Role of Type 2 Inflammation in Bullous Pemphigoid (BP)

ADVENT On Air | Getting to Grips With Atopic Hand and Foot Dermatitis: What Is It, and What Does It Mean for Patients?
Dermatology
Podcast

ADVENT On Air | Getting to Grips With Atopic Hand and Foot Dermatitis: What Is It, and What Does It Mean for Patients?

The Role of Type 2 Inflammation in Multiple Disease Trajectories
Dermatology
Infographic

The Role of Type 2 Inflammation in Multiple Disease Trajectories

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-US-2305040 v3.0-P Exp. Date: 11/24/2025

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: United StatesChange country/region